DLDekang Lv

Dekang Lv

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dekang Lv has a total of 103 co-authors. Here are the top co-authors by number of shared publications:

  • Chanjun Sun

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Chen Ni

    Medical Research Center, Henan China-Germany International Joint Laboratory of Tumor Immune Microenvironment and Disease, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

    2 shared publications
  • Jiajia Wan

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Jialu Liang

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Kaili Zhang

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Li Zhang

    Medical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

    2 shared publications

Latest Publications

  • Open Access

    Glycolytic enolase 1-induced H4K12 lactylation activates quiescent breast cancer stem-like cells in triple-negative breast cancer

    by Shuai Liu, Yunfeng Ma, Yujie Zeng, Dekang Lv, Zhijie Hou, Junxiu Huang, Yaqi Gong, Ruijun Feng, Zihan Wang, Ran Sui, et al.

    Activation of quiescent or extremely slow-cycling breast cancer stem-like cells (qsBCSCs) contributes to tumor progression, yet the regulatory mechanisms involved in triple-negative breast cancer (TNBC) remain elusive. We developed a dual-reporter system combining NANOG-EGFP and H2B-mCherry pulse-chase labeling to separately identify qsBCSCs and active BCSCs (aBCSCs) in vitro and in vivo. aBCSCs display significant enrichment of glycolysis and lactylation signatures, a finding corroborated by single-cell RNA sequencing (scRNA-seq) of TNBC patient samples. Glycolytic enzyme Enolase 1 (ENO1) expression is positively correlated with elevated histone H4 lysine 12 lactylation (H4K12la) in aBCSCs. Functional studies revealed a positive feedback circuit in which ENO1-increased lactate promotes H4K12la, which in turn activates ENO1 transcription. The ENO1-lactate-H4K12la axis enhances proliferating cell nuclear antigen (PCNA) transcription to activate qsBCSCs. Suppression of ENO1 or H4K12la prevents PCNA upregulation and qsBCSC activation. Importantly, PCNA knockdown alone blocks the activation of qsBCSCs induced by exogenous sodium L-lactate (NALA). In orthotopic breast cancer mouse models, both genetic depletion of ENO1 and pharmacological inhibition of lactate production attenuated tumor growth by blocking qsBCSC activation. Clinically, ENO1 expression was strongly correlated with PCNA expression, with high expression predicting poor OS, RFS, and DMFS. Our results establish the ENO1-H4K12la-PCNA axis as a key metabolic‒epigenetic driver of qsBCSC activation and a therapeutic target in TNBC.


  • Open Access

    FigureYa: A Standardized Visualization Framework for Enhancing Biomedical Data Interpretation and Research Efficiency

    by Xiaofan Lu, Kailai Li, Zongcheng Li, Anqi Lin, Long Zhao, Rongfang Shen, Zhougeng Xu, Jianing Gao, Dekang Lv, Yasi Zhang, et al.

    Biomedical research data visualization faces several challenges, including insufficient expertise and fragmented methodologies, which severely limit research efficiency and result quality. FigureYa is a standardized visualization framework composed of 317 modular R/python scripts, rather than a standalone software or desktop application. It covers key domains such as expression profiling, immune analysis, survival analysis, and single‐cell data visualization. Based on the concept of “replace data and use,” FigureYa significantly lowers the technical threshold, allowing researchers to generate high‐quality charts without requiring an extensive programming background. Compared to generic online R code snippets, FigureYa offers rigorously developed, thoroughly validated, and biologically contextualized visualization modules originally written by the author team. Each script includes version‐matched environments, example datasets, and detailed annotations, providing clear advantages in automation, reproducibility, and scientific professionalism, thereby providing a standardized visualization solution for complex biomedical data. This innovative tool optimizes research time allocation, promotes interdisciplinary collaboration, accelerates scientific discovery and clinical translation, and provides robust data visualization support for biomedical research.


  • Open Access

    Author Correction: ZIP1+ fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn2+ transfer

    by Chen Ni, Xiaohan Lou, Xiaohan Yao, Linlin Wang, Jiajia Wan, Xixi Duan, Jialu Liang, Kaili Zhang, Yuanyuan Yang, Li Zhang, et al.

  • Open Access

    ZIP1+ fibroblasts protect lung cancer against chemotherapy via connexin-43 mediated intercellular Zn2+ transfer

    by Chen Ni, Xiaohan Lou, Xiaohan Yao, Linlin Wang, Jiajia Wan, Xixi Duan, Jialu Liang, Kaili Zhang, Yuanyuan Yang, Li Zhang, et al.

    Tumour–stroma cell interactions impact cancer progression and therapy responses. Intercellular communication between fibroblasts and cancer cells using various soluble mediators has often been reported. In this study, we find that a zinc-transporter (ZIP1) positive tumour-associated fibroblast subset is enriched after chemotherapy and directly interconnects lung cancer cells with gap junctions. Using single-cell RNA sequencing, we identify several fibroblast subpopulations, among which Zip1+ fibroblasts are highly enriched in mouse lung tumours after doxorubicin treatment. ZIP1 expression on fibroblasts enhances gap junction formation in cancer cells by upregulating connexin-43. Acting as a Zn2+ reservoir, ZIP1+ fibroblasts absorb and transfer Zn2+ to cancer cells, leading to ABCB1-mediated chemoresistance. Clinically, ZIP1high stromal fibroblasts are also associated with chemoresistance in human lung cancers. Taken together, our results reveal a mechanism by which fibroblasts interact directly with tumour cells via gap junctions and contribute to chemoresistance in lung cancer.


  • Open Access

    Transcriptomic but not genomic variability confers phenotype of breast cancer stem cells

    by Mengying Tong, Ziqian Deng, Mengying Yang, Chang Xu, Xiaolong Zhang, Qingzheng Zhang, Yuwei Liao, Xiaodi Deng, Dekang Lv, Xuehong Zhang, et al.

    Background: Breast cancer stem cells (BCSCs) are considered responsible for cancer relapse and drug resistance. Understanding the identity of BCSCs may open new avenues in breast cancer therapy. Although several discoveries have been made on BCSC characterization, the factors critical to the origination of BCSCs are largely unclear. This study aimed to determine whether genomic mutations contribute to the acquisition of cancer stem‐like phenotype and to investigate the genetic and transcriptional features of BCSCs. Methods: We detected potential BCSC phenotype‐associated mutation hotspot regions by using whole‐genome sequencing on parental cancer cells and derived serial‐generation spheres in increasing order of BCSC frequency, and then performed target deep DNA sequencing at bulk‐cell and single‐cell levels. To identify the transcriptional program associated with BCSCs, bulk‐cell and single‐cell RNA sequencing was performed. Results: By using whole‐genome sequencing of bulk cells, potential BCSC phenotype‐associated mutation hotspot regions were detected. Validation by target deep DNA sequencing, at both bulk‐cell and single‐cell levels, revealed no genetic changes specifically associated with BCSC phenotype. Moreover, single‐cell RNA sequencing showed profound transcriptomic variability in cancer cells at the single‐cell level that predicted BCSC features. Notably, this transcriptomic variability was enriched during the transcription of 74 genes, revealed as BCSC markers. Breast cancer patients with a high risk of relapse exhibited higher expression levels of these BCSC markers than those with a low risk of relapse, thereby highlighting the clinical significance of predicting breast cancer prognosis with these BCSC markers. Conclusions: Transcriptomic variability, not genetic mutations, distinguishes BCSCs from non‐BCSCs. The identified 74 BCSC markers have the potential of becoming novel targets for breast cancer therapy.